- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00883779
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
November 10, 2015 updated by: Hoffmann-La Roche
A Randomized, Placebo-controlled, Double-blind Phase III Study of the Effect of First-line Treatment With Intercalated Tarceva Versus Placebo in Combination With Gemcitabine/Platinum on Progression-free Survival in Patients With Stage IIIB/IV Non-small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva or placebo, plus platinum-based therapy, as first line treatment in patients with advanced or recurrent non-small cell lung cancer.
Patients will be randomized to receive gemcitabine (1250mg/m2 iv) on days 1 and 8, and cisplatin (75mg/m2) or carboplatin (5xAUC)on day 1, followed by Tarceva 150mg/day or placebo from day 15 to day 28 of each 4 week cycle for a total of 6 cycles,then followed by Tarceva or placebo monotherapy.The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
451
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100021
-
Beijing, China, 100142
-
Beijing, China, 101149
-
Guangzhou, China
-
Guangzhou, China, 510060
-
Hangzhou, China
-
Nanjing, China, 210029
-
Shanghai, China, 200433
-
Shanghai, China, 200030
-
-
-
-
-
Hong Kong, Hong Kong
-
Hong Kong, Hong Kong, 852
-
Shatin, Hong Kong
-
-
-
-
-
Jakarta, Indonesia, 13230
-
Jogjakarta, Indonesia, 55284
-
Surabaya, Indonesia, 60286
-
-
-
-
-
Gyeonggi-do, Korea, Republic of, 410-769
-
-
-
-
-
Manila, Philippines, 1000
-
Pasig City, Philippines, 1605
-
Quezon City, Philippines, 1104
-
-
-
-
-
Taichung, Taiwan, 407
-
Taipei, Taiwan
-
Taipei, Taiwan, 100
-
Taipei, Taiwan, 116
-
-
-
-
-
Bangkok, Thailand, 10400
-
Bangkok, Thailand, 10700
-
Chiang Mai, Thailand, 50200
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- adult patients, >=18 years of age;
- advanced (stage IIIB/IV)non-small cell lung cancer;
- measurable disease;
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
Exclusion Criteria:
- prior exposure to agents directed at the HER axis;
- prior chemotherapy or systemic anti-tumor therapy after advanced disease;
- unstable systemic disease;
- any other malignancy within last 5 years, except cured basal cell cancer of skin or cured cancer in situ of cervix;
- brain metastasis or spinal cord compression.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles
150mg po on days 15-28 of each 4 week cycle until disease progression
1250mg/m2 iv on days 1 and 8 of each 4 week cycle for 6 cycles
|
Placebo Comparator: 2
|
cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles
1250mg/m2 iv on days 1 and 8 of each 4 week cycle for 6 cycles
po on days 15-28 of each 4 week cycle until disease progression
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Progression Free Survival (PFS) Time
Time Frame: Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])
|
Tumor response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0).
PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.
PFS is the time (in months) between the date of randomization and the date of first documented disease progression or death from any cause, whichever comes first.
Participants who had neither progressed nor died at the time of data cut-off or who were lost to follow-up were censored at the date of the last tumor assessment where non-progression was documented or last date of follow up for progression of disease, whichever was last.
Participants without post baseline tumor assessments who were known to be alive were censored at the time of randomization.
Analysis was performed using Kaplan-Meier method.
|
Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Alive and Free From Disease Progression
Time Frame: Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])
|
Tumor response was evaluated according to RECIST (version 1.0).
PD was defined as at least a 20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.
|
Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])
|
Median PFS Time Based on Different Subgroups
Time Frame: Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])
|
Tumor response was evaluated according to RECIST (version 1.0).
PD was defined in outcome measure 1. PFS is the time (in months) between the date of randomization and the date of first documented disease progression or death from any cause, whichever comes first.
Participants who had neither progressed nor died at the time of data cut-off or who were lost to follow-up were censored at the date of the last tumor assessment where non-progression was documented or last date of follow up for progression of disease, whichever was last.
Participants without post baseline tumor assessments who were known to be alive were censored at the time of randomization.
PFS among different subgroups of type of carcinoma, smoking habit, epidermal growth factor receptor (EGFR) mutation type, KRAS mutation type, EGFR immunohistochemistry (IHC) test result type, and EGFR fluorescent in situ hybridization (FISH) result type.
|
Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])
|
Median Overall Survival (OS) Time-Overall and Among Different Subgroups
Time Frame: Randomization until death (assessed at baseline and every 8 weeks thereafter until death or end of study [up to approximately 5.5 years])
|
OS was defined as the time between the date of randomization and the date of death from any cause.
Participants for whom no death was captured on the clinical database were censored at the most recent date they were known to be alive.
Participants with no post baseline information were censored at the time of randomization.
OS among different subgroups of type of carcinoma, smoking habit, EGFR mutation type, KRAS mutation type, EGFR IHC test result type, and EGFR FISH result type.
Analysis was performed using Kaplan-Meier method.
|
Randomization until death (assessed at baseline and every 8 weeks thereafter until death or end of study [up to approximately 5.5 years])
|
Percentage of Participants Alive at the End of Study-Overall and Among Different Subgroups
Time Frame: Randomization until death (assessed at baseline and every 8 weeks thereafter until death or end of study [up to approximately 5.5 years])
|
Randomization until death (assessed at baseline and every 8 weeks thereafter until death or end of study [up to approximately 5.5 years])
|
|
Non-Progression Rate: Percentage of Participants With a Confirmed Best Overall Response of Either Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) for At Least 16 Weeks
Time Frame: Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])
|
Tumor response was evaluated according to RECIST (version 1.0).
CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level; PR is defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the screening sum LD; SD for target lesions is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started and SD for non-target lesions defined as persistence of 1 or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
Responses were confirmed with repeated assessment 4 weeks after initial response was observed.
|
Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])
|
Objective Response Rate: Percentage of Participants With a Confirmed Best Overall Response of CR or PR
Time Frame: Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])
|
Tumor response was evaluated according to RECIST (version 1.0).
CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level; PR is defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the screening sum LD.
Responses were confirmed with repeated assessment 4 weeks after initial response was observed.
|
Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])
|
Duration of Response
Time Frame: Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])
|
Duration of response is defined as the time between the date of first documented response (CR or PR, as determined by the RECIST criteria) and the date of first documented PD or death.
Participants who did not progress or die after they had a confirmed response (CR or PR) were censored at the date of their last tumor assessment where non-progression was documented or last date of follow-up for progression of disease, whichever was last.
CR and PR are defined in Outcome Measure 7.
|
Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])
|
Time to Progression
Time Frame: Randomization until PD (assessed at baseline and every 8 weeks thereafter until PD or end of study [up to approximately 1.5 years])
|
Time to progression is defined as the time between the date of randomization and the date of the first documented disease progression.
Participants who have not progressed at the time of study completion (or data cut off) or who were lost to follow up were censored at the date of the last tumor assessment where non-progression was documented or last date of follow-up for progression of disease, whichever was latest.
PD was defined as at least a 20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.
Participants with no post baseline tumor assessments were censored at the time of randomization.
Analysis was performed using Kaplan-Meier method.
|
Randomization until PD (assessed at baseline and every 8 weeks thereafter until PD or end of study [up to approximately 1.5 years])
|
Percentage of Participants With Symptomatic Progression Assessed Using the Lung Cancer Subscale (LCS)
Time Frame: Baseline, Day 1 of Cycles 3 and 5, Day 1 of post-study Visits 1 and 2 until end of study medication administration or PD (up to approximately 1.5 years)
|
LCS scores were obtained from a 7-item questionnaire from the Functional Assessment of Cancer Therapy - Lung (FACT-L) (version 4.0).
Participants responded to questions such as shortness of breath, cough, tightness in chest, breathing difficulty, appetite loss, weight loss and unclear thinking; on a 5-point scale from 0-4, where 0 equaled (=) "not at all" and 4 = "very much."
The participants' responses were summed to result in an overall score, scores range on a scale of 0 (most symptomatic) to 28 (asymptomatic); higher score indicates fewer symptoms.
A clinically meaningful decline used to determine symptomatic progression in this study was at least a three point decline in LCS score from baseline.
Participants without symptomatic progression at the time of analysis were censored at the time of the last FACT-L assessment.
|
Baseline, Day 1 of Cycles 3 and 5, Day 1 of post-study Visits 1 and 2 until end of study medication administration or PD (up to approximately 1.5 years)
|
Time to Symptomatic Progression
Time Frame: Baseline, Day 1 of Cycles 3 and 5, Day 1 of post-study Visits 1 and 2 until end of study medication administration or PD (up to approximately 1.5 years)
|
Time to symptomatic progression was the time from randomization until the earlier of a clinically meaningful decline from baseline in LCS score, or death on study.
LCS scores were obtained from a 7-item questionnaire from the FACT-L (version 4.0).
Participants responded to questions such as shortness of breath, cough, tightness in chest, breathing difficulty, appetite loss, weight loss and unclear thinking; on a 5-point scale from 0-4, where 0 = "not at all" and 4 = "very much."
The participants' responses were summed to result in an overall score, scores range on a scale of 0 (most symptomatic) to 28 (asymptomatic); higher score indicates fewer symptoms.
A clinically meaningful decline used to determine symptomatic progression in this study was at least a three point decline in LCS score from baseline.
Participants without symptomatic progression at the time of analysis were censored at the time of the last FACT-L assessment.
Analysis was performed using Kaplan-Meier method.
|
Baseline, Day 1 of Cycles 3 and 5, Day 1 of post-study Visits 1 and 2 until end of study medication administration or PD (up to approximately 1.5 years)
|
Percentage of Participants With Deterioration in Trial Outcome Index (TOI) Using FACT-L Version 4.0
Time Frame: Baseline, Day 1 of Cycles 3 and 5, Day 1 of post-study Visits 1 and 2 until end of study medication administration or PD (up to approximately 1.5 years)
|
TOI was defined as the sum of the scores of the Physical Well-Being (PWB), Functional Well-Being (FWB), and LCS.
PWB, FWB, and LCS scores were obtained from 7-item questionnaires from the FACT-L (Version 4.0).
Participants responded to questions on a 5-point scale from 0-4, where 0 = "not at all" and 4 = "very much."
The participants' responses were summed to result in an overall score, scores range on a scale of 0 to 84; higher score indicates better physical aspects of quality of life (QoL).
A clinically meaningful decline used to determine deterioration in TOI was greater than or equal to (≥) 6-point decline from baseline.
Participants without deterioration in TOI at the time of analysis were censored at the time of the last FACT-L assessment.
|
Baseline, Day 1 of Cycles 3 and 5, Day 1 of post-study Visits 1 and 2 until end of study medication administration or PD (up to approximately 1.5 years)
|
Time to Deterioration in TOI Using FACT-L Version 4.0
Time Frame: Baseline, Day 1 of Cycles 3 and 5, Day 1 of post-study Visits 1 and 2 until end of study medication administration or PD (up to approximately 1.5 years)
|
Time to deterioration in TOI is defined as time from randomization until the earlier of a clinically meaningful decline from baseline in TOI or death on study.
TOI is defined as the sum of the scores of the PWB, FWB, and LCS.
PWB, FWB, and LCS scores were obtained from 7-item questionnaires from the FACT-L (Version 4.0).
Participants responded to questions on a 5-point scale from 0-4, where 0 = "not at all" and 4 = "very much."
The participants' responses were summed to result in an overall score, scores range on a scale of 0 to 84; higher score indicates better physical aspects of QoL.
A clinically meaningful decline used to determine deterioration in TOI was ≥6-point decline from baseline.
Participants without deterioration in TOI at the time of analysis were censored at the time of the last FACT-L assessment.
Analysis was performed using Kaplan-Meier method.
|
Baseline, Day 1 of Cycles 3 and 5, Day 1 of post-study Visits 1 and 2 until end of study medication administration or PD (up to approximately 1.5 years)
|
Percentage of Participants With Deterioration in Quality of Life (QOL) Using FACT-L Version 4.0
Time Frame: Baseline, Day 1 of Cycles 3 and 5, Day 1 of post-study Visits 1 and 2 until end of study medication administration or PD (up to approximately 1.5 years)
|
Total FACT-L score was defined as the sum of the TOI, Social Well Being (SWB) and EWB of the FACT-L questionnaires.
TOI (PWB + FWB + LCS), SWB and EWB scores were obtained from 7-item (6-item in the case of EWB) questionnaires from the FACT-L (Version 4.0).
Participants responded to questions on a 5-point scale from 0-4, where 0 = "not at all" and 4 = "very much."
The participants' responses were summed to result in an overall score, scores range on a scale of 0 to 136; higher score indicates better QoL.
A clinically meaningful decline used to determine deterioration in QoL was ≥6-point decline from baseline.
Participants without deterioration in QoL at the time of analysis were censored at the time of the last FACT-L assessment.
|
Baseline, Day 1 of Cycles 3 and 5, Day 1 of post-study Visits 1 and 2 until end of study medication administration or PD (up to approximately 1.5 years)
|
Time to Deterioration in QOL Using FACT-L Version 4.0
Time Frame: Baseline, Day 1 of Cycles 3 and 5, Day 1 of post-study Visits 1 and 2 until end of study medication administration or PD (up to approximately 1.5 years)
|
Time to deterioration in QoL is defined as time from randomization until the earlier of a clinically meaningful decline from baseline in Total FACT-L or death on study.
Total FACT-L score was defined as the sum of the TOI, SWB and EWB of the FACT-L questionnaires.
TOI (PWB + FWB + LCS), SWB and EWB scores were obtained from 7-item (6-item in the case of EWB) questionnaires from the FACT-L (Version 4.0).
Participants responded to questions on a 5-point scale from 0-4, where 0 = "not at all" and 4 = "very much."
The participants' responses were summed to result in an overall score, scores range on a scale of 0 to 136; higher score indicates better QoL.
A clinically meaningful decline used to determine deterioration in QoL was ≥6-point decline from baseline.
Participants without deterioration in QoL at the time of analysis were censored at the time of the last FACT-L assessment.
Analysis was performed using Kaplan-Meier method.
|
Baseline, Day 1 of Cycles 3 and 5, Day 1 of post-study Visits 1 and 2 until end of study medication administration or PD (up to approximately 1.5 years)
|
Median Follow-up Time During the Study
Time Frame: Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 5.5 years])
|
Median follow-up was calculated using 'Reverse Kaplan-Meier' analysis for Overall survival.
|
Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 5.5 years])
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (Actual)
December 1, 2014
Study Completion (Actual)
December 1, 2014
Study Registration Dates
First Submitted
April 15, 2009
First Submitted That Met QC Criteria
April 17, 2009
First Posted (Estimate)
April 20, 2009
Study Record Updates
Last Update Posted (Estimate)
December 14, 2015
Last Update Submitted That Met QC Criteria
November 10, 2015
Last Verified
November 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protein Kinase Inhibitors
- Gemcitabine
- Carboplatin
- Erlotinib Hydrochloride
- Cisplatin
Other Study ID Numbers
- MO22201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Squamous Non-Small Cell Lung Cancer
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
AIO-Studien-gGmbHAstraZenecaTerminatedNSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR MutationGermany
-
Western Regional Medical CenterTerminatedNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer | Squamous Cell Non-Metastatic Non-Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic...United States
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
Hoffmann-La RocheCompletedNon-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung CancerSpain, Italy, Poland, Brazil, Turkey, Serbia, France, Korea, Republic of, Romania, Hungary, Russian Federation, United States, United Kingdom, Germany, Greece, Japan, Thailand, Ukraine, China
-
Bristol-Myers SquibbNo longer availableNon-squamous Non-Small Cell Lung Cancer | Squamous Non-Small Cell Lung CancerBrazil, Canada
-
European Organisation for Research and Treatment...WithdrawnSquamous Non-small Cell Lung Cancer | Non-Squamous Non-small Cell Lung Cancer
-
National Cancer Institute (NCI)RecruitingStage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell CarcinomaUnited States
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
Clinical Trials on Platinum chemotherapy (cisplatin or carboplatin)
-
Seoul National University HospitalNot yet recruiting
-
University of Michigan Rogel Cancer CenterRecruitingOropharynx Cancer | HPV-Related CarcinomaUnited States
-
Merck KGaA, Darmstadt, GermanyCompletedHead and Neck CancerFrance, Russian Federation, Spain, United Kingdom, Germany, Hungary, Poland, Ukraine, Austria, Netherlands, Slovakia, Sweden, Switzerland, Belgium, Italy, Portugal, Czech Republic
-
Shanghai Chest HospitalUnknownRadiotherapy | Non-small Cell Lung Cancer Stage IIIAChina
-
Shanghai Chest HospitalFudan University; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsUnknownRadiotherapy | Non-small Cell Lung Cancer Stage IIIAChina
-
Genprex, Inc.RecruitingCarcinoma, Non-Small Cell LungUnited States
-
Daiichi Sankyo, Inc.CompletedSquamous Cell Carcinoma of the Head and NeckUnited Kingdom
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
Memorial Sloan Kettering Cancer CenterMayo Clinic; University of Chicago; University of Pittsburgh; Baptist Health South... and other collaboratorsActive, not recruitingOvarian Cancer | Peritoneal Cancer | Fallopian Tubes CancerUnited States
-
BeiJing Yijiayi Medicine Techonoloy Co., Ltd.Hubei Mon Yan Pharmaceutical Co., LtdUnknownNon-small-Cell Lung CancerChina